Biosimilars
News
Amphastar and Watson launch biosimilar enoxaparin
posted 07/02/2012
US generics manufacturer Watson Pharmaceuticals announced on 26 January 2012 that Amphastar Pharmaceuticals and Watson had be... 
Production of 24 biosimilars in Iran by 2012
posted 07/02/2012
According to reports on Press TV— 24-hour English language global news network owned by the state-owned media corporation Isl... 
Sandoz starts phase III trials for biosimilar filgrastim and pegfilgrastim
posted 27/01/2012
On 19 January 2012, Sandoz, the generic drug division of Swiss drug giant Novartis AG, announced that it had started two phas... 
Roche encounters manufacturing issues with epoetin-beta
posted 27/01/2012
The Spanish regulatory agency has found deviations in the quality of the manufacture of Switzerland-based F. Hoffmann-La Roch... 
Baxter and Momenta make biosimilars deal
posted 20/01/2012
Baxter International (Baxter) and Momenta Pharmaceuticals (Momenta) announced on 22 December 2011 that they had entered into... |
Research
Factors affecting market access of biosimilars
posted 07/02/2012
Growth in the use of biosimilars is being driven by the need to reduce healthcare costs, patent expiries on blockbuster origi... 
Physician perceptions of generics substitution
posted 27/01/2012
How do physicians perceive generics substitution? Many patients do not communicate with their physicians regarding out-of-poc... 
Relative effectiveness and cost minimisation for biosimilars
posted 24/01/2012
The second of two articles on the use of economic evaluations to guide the use of expensive treatment. 
The cost-effectiveness of biosimilars
posted 20/01/2012
The biotechnology market is growing rapidly, driven by the imminent patent expiry of several major biologicals and enabled by... 
Economic evaluation of biosimilars
posted 20/01/2012
Biological drugs represent a fast-growing segment of the pharmaceutical market. They make up 32% of drugs in the development... |
General
Top developments in biosimilars during 2011
posted 13/01/2012
Over the past year, a lot has happened in the biosimilars industry. 
FDA biosimilar user fees meeting
posted 16/12/2011
FDA announced a public meeting to be held on 16 December 2011 to discuss its recommendations for the agency’s biosimilars use... 
Health Canada definitions of generics and biosimilars
posted 16/12/2011
Attention has been brought to the fact that there is confusion surrounding terms used in the global field of generics and bio... 
Speed to market critical in biosimilar development
posted 21/11/2011
For companies looking to develop biosimilars speed to market is critical, but this must not be done by sacrificing product qu... 
FDA definitions of generics and biosimilars
posted 21/11/2011
Confusion surrounding terms used in the global field of generics and biosimilars is a recognised problem.The source of some o... |